Latest Activity
Mounjaro nearly doubled to $9.94 billion, pushing Lilly to lift full-year revenue guidance to $85 billion to $87 billion. Retatrutide's filing in early 2027 is the next catalyst.
LLY Coverage
Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker
Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only…
700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3
Roughly 700,000 seniors have started GLP-1 obesity treatments since Medicare’s Bridge program launched July 1, 2026, according to Eli Lilly (NYSE:LLY | LLY Price Prediction) CEO David Ricks. Eligible beneficiaries pay $50…
Prediction: Eli Lilly’s Next Growth Wave Could Surprise Investors
Eli Lilly is growing faster than any other mega-cap drugmaker, but a pipeline drug still awaiting approval and falling U.S. prices are pulling the stock in opposite directions. The outcome of that…
He Will Switch Contractors to Help Build Eli Lilly’s $6.5 Billion Plant. Two W-2s Could Put $2,821 in Social Security Taxes Back in His Pocket
A pipefitter switching contractors during construction of a massive new pharmaceutical plant could walk away from tax season with a surprise windfall, and most workers in the same situation never even realize…
Gerelyn Terzo Eli Lilly Wavered Over the Last Month: One of Wall Street’s Biggest Banks Says 35% Gains Still to Come
Citigroup sees a path to 35% gains from here, but Eli Lilly's pricing headwinds, a slow oral GLP-1 launch, and a rival in freefall raise a real question about whether this pause…
Eli Lilly Just Won FDA Approval for a Once Weekly Insulin and the Stock Is Knocking on $1,200
The FDA just handed Eli Lilly a new diabetes approval, but the real debate is whether a once-weekly insulin needle moves the needle on a stock already up 60% and closing in…
Omor Ibne Ehsan Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year
Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most…
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether…
His Bet On Home Depot Made Ken Langone A Billionaire. Now He Sees Eli Lilly Stock Hitting $2,000
Ken Langone, chairman and president of Invemed Associates and a co-founder of Home Depot (NYSE:HD | HD Price Prediction), used a CNBC Squawk Box appearance on September 22, 2026 to say that…
Eli Lilly’s Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon
Eli Lilly just posted a quarter that crushed estimates on every major metric, yet the stock has spent the past month getting punished anyway. One of Wall Street's biggest banks thinks the…
The Next Chapter of Eli Lilly Could Be Bigger Than Investors Expect
Eli Lilly is posting 48% revenue growth while its stock sits nearly flat for the year, and that disconnect points to something Wall Street may be mispricing entirely.
Vandita Jadeja Nvidia vs. Eli Lilly: I’d Choose This Stock for the Next Decade
NVIDIA and Eli Lilly both shattered expectations this quarter, but picking the better stock for the next decade means choosing between two very different growth machines at very different levels of risk.
Novo Nordisk Falls 7% as Post-Wegovy Growth Plan Fails to Ease Competition Fears; Eli Lilly Slips, Viking Therapeutics Edges Higher
Novo Nordisk (NYSE:NVO | NVO Price Prediction) laid out its long-term growth strategy at a capital markets day in London Monday morning, and the plan didn’t calm investor worries about the company’s…
Can Eli Lilly’s Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?
Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble…
There Are Plenty of Eli Lilly Bulls: Here’s What They Aren’t Telling You
Eli Lilly's bulls are pointing at a 47% revenue surge and a pipeline loaded with blockbuster candidates, but there are a few uncomfortable details quietly buried in the earnings report that change…